Literature DB >> 2681969

Endocrine and metabolic abnormalities following kidney transplantation.

W H Hörl1, W Riegel, C Wanner, M Haag-Weber, P Schollmeyer, H Wieland, H Wilms.   

Abstract

Various endocrine and metabolic disturbances associated with long standing uremia persist after kidney transplantation or arise from the use of immunosuppressive drugs. Hyperlipidemia for long time being implicated as the cause of corticosteroids is also observed in renal transplant recipients treated with cyclosporin A monotherapy. After conversion from cyclosporin to azathioprine serum cholesterol and triglyceride concentration fall, and elevation of LDL-cholesterol may also be reversed. There is a tendency for higher HDL-cholesterol in azathioprine and prednisolone treated transplant patients. Those patients who are at risk for clinically significant cholesterol elevations can be predicted by their pretransplant lipid levels, specifically the LDL-fraction. Risk-benefit ratio of conversion and of treatment with lipid-lowering drugs, especially with lovastatin, should be carefully examined, also in view of glucose intolerance. Higher incidence of diabetes mellitus requiring insulin therapy in cyclosporin treated transplant recipients has been reported. Cyclosporin may cause toxic effects on pancreatic beta-cells resulting in inhibition of insulin secretion. High doses of cyclosporin induce inhibition of glycogen synthesis in rat liver. Glucose intolerance is reversible after reduction of cyclosporin dose or conversion to azathioprine. Therefore glucose metabolism in kidney transplant recipients treated with cyclosporin should be carefully followed. Immunosuppressive therapy may affect reproductive function, arachidonate metabolism and renin-angiotensin-aldosterone system as well as posttransplant calcium and phosphate metabolism. Endocrine and metabolic abnormalities are associated with long standing uremia. After successful kidney transplantation several observations are normalized but further complications arise from the use of immunosuppressive drugs. The present paper reviews various endocrine and metabolic disturbances described following renal transplantation.

Entities:  

Mesh:

Year:  1989        PMID: 2681969     DOI: 10.1007/bf01717348

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  131 in total

1.  Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

Authors:  K P Harris; G I Russell; S D Parvin; P S Veitch; J Walls
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

2.  Glybenclamide and cyclosporine A: an interaction on glucose metabolism.

Authors:  V Hopps; A Galione; P Vetri; F Vaccaro; M C Sorrentino; M E Woodrow
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

3.  High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia.

Authors:  J Nemunaitis; H J Deeg; G C Yee
Journal:  Lancet       Date:  1986-09-27       Impact factor: 79.321

4.  Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation.

Authors:  K Jung; A Scheifler; W Blank; D Scholz; B D Schulze; C Hansen
Journal:  Transplantation       Date:  1988-09       Impact factor: 4.939

5.  Leukocyte metabolism and function in uremia.

Authors:  W A Briggs; D H Sillix; S Mahajan; F D McDonald
Journal:  Kidney Int Suppl       Date:  1983-12       Impact factor: 10.545

6.  [Cyclosporin A and hyperlipidemia after kidney transplantation. Prospective study].

Authors:  K Hodel; R C Mordasini; F P Brunner; G Thiel
Journal:  Schweiz Med Wochenschr       Date:  1986-06-28

7.  Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins?

Authors:  N Perico; A Benigni; E Bosco; M Rossini; S Orisio; F Ghilardi; A Piccinelli; G Remuzzi
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

8.  Inhibited efficiency of kidney mitochondria isolated from rats treated with cyclosporin A.

Authors:  K Jung; C Reinholdt; D Scholz
Journal:  Nephron       Date:  1987       Impact factor: 2.847

9.  Interference by cyclosporine with the endocrine function of the canine pancreas.

Authors:  R van Schilfgaarde; M P van der Burg; P T van Suylichem; M Frölich; H G Gooszen; A J Moolenaar
Journal:  Transplantation       Date:  1987-07       Impact factor: 4.939

10.  Effect of cyclosporine on steroidogenesis in rat Leydig cells.

Authors:  S C Sikka; D C Coy; C A Lemmi; J Rajfer
Journal:  Transplantation       Date:  1988-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.